No Data
Incyte, Mirum Pharmaceuticals to Present New Zilurgisertib Study Results at Conference
Mirum Expands Long-Term Safety Data for Livmarli in Rare Pediatric Liver Diseases
Mirum Pharmaceuticals Insider Sold Shares Worth $2,875,103, According to a Recent SEC Filing
Citi Initiates Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Announces Target Price $145
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Mirum Pharmaceuticals (MIRM) and Corbus Pharmaceuticals (CRBP)
Express News | Mirum Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $145